Jiangsu Hengrui Medicine Co., Ltd.

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
45.61 ^CNY	+2.96%		+9.43%	+0.84%

Apr. 26	Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	MT
Apr. 17	Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.

January 02, 2024

From October 1, 2023 to December 31, 2023, the company has repurchased 550,000 shares, representing 0.008981% for CNY 24.63 million. With this, the company has completed the repurchase of 14,112,323 shares, representing 0.22% for CNY 624.66 million under the buyback announced on May 15, 2023.

Latest news about Jiangsu Hengrui Medicine Co., Ltd.

Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	Apr. 26	MT
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 17	CI
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 17	CI
Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	Apr. 11	MT
China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs	Apr. 10	MT
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs	Apr. 09	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Apr. 01	CI
Hengrui Pharma Gets Nod for Injectable Cancer Drug Trial	Mar. 27	MT
Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs	Mar. 19	MT
Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral	Mar. 15	MT
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE
Hengrui Pharma Gets Green Light to Trial Tumor Drug Combination	Feb. 29	MT
Hengrui Pharma Gets China Nod to Trial Combo Treatment for Breast Cancer	Feb. 28	MT
US FDA Gives Fast Track Designation to Hengrui Pharma's Lymphoma Drug	Feb. 22	MT
Hengrui Pharma's Unit Gets Nod to Trial Adebelimab Injection	Feb. 22	MT
GSK completes acquisition of Aiolos Bio for up to $1.4 bln	Feb. 15	RE
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	Feb. 07	CI
Cancer Drug of Hengrui Pharmaceuticals' Unit Placed in China's List of Breakthrough Therapy Drugs; Shares Climb 4%	Feb. 05	MT
Hengrui Pharmaceuticals Gets Nod for Taglidine Fumarate Injection	Feb. 01	MT
Hengrui Pharmaceuticals' Subsidiary Gets US FDA's Nod for Tacrolimus Capsules	Jan. 30	MT
Hengrui Pharma's Unit Gets Nod to Trial Adbelimab Injection	Jan. 17	MT
Hengrui Pharmaceuticals, Subsidiary Get Chinese Drug Regulator's Nod for Two Drugs	Jan. 08	MT
Chinese Shares Finish Lower Ahead of US Jobs Data; Hengrui Pharma Slides 4% on New Drug Approvals	Jan. 05	MT
China money managers rush to create funds tracking new A50 index	Jan. 03	RE
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Jan. 02	CI

Chart Jiangsu Hengrui Medicine Co., Ltd.

Duration

Period

Chart Jiangsu Hengrui Medicine Co., Ltd.

More charts

Company Profile

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Hengrui Medicine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.61 CNY

Average target price

57.6 CNY

Spread / Average Target

+26.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU HENGRUI MEDICINE CO., LTD.	+0.84%	40.02B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

Pharmaceuticals

Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.

EPS Revisions